Novel BRAF mutation in melanoma: A case report

Trubini,Serena; Ubiali,Alessandro; Paties,Carlo   Terenzio; Cavanna,Luigi

doi:10.3892/mco.2018.1555

Novel BRAF mutation in melanoma: A case report

Authors:
- Serena Trubini
- Alessandro Ubiali
- Carlo Terenzio Paties
- Luigi Cavanna
View Affiliations

Affiliations: Onco‑Hematologic Department, Ospedale Guglielmo da Saliceto, I‑49‑29121 Piacenza, Italy
Published online on: January 12, 2018 https://doi.org/10.3892/mco.2018.1555
Pages: 460-462

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

In melanoma, a number of specific genetic and genomic aberrations have been identified to be important in tumorigenesis. In particular, the mutant B‑Raf proto‑oncogene, Serine/Threonine kinase (BRAF) gene is the target of tailored therapy with kinase inhibitor molecules. Identification of the array of mutations in patients with melanoma will be useful in determining a genetic profile of the tumor with potential implications for treatment decisions. A rare aminoacidic insertion in codon 599 of the BRAF gene (c.1797_1798insACA, T599insT) was detected by using both direct (Sanger) sequencing and pyrosequencing techniques in a metastatic melanoma of a female elderly patient. As suggested in other clinical contexts including pilocytic astrocytoma, papillary thyroid carcinomas and anaplastic thyroid carcinomas, this unusual mutation may be associated with a modified spatial structure of activated P‑loop, resulting in a constitutional activation of the BRAF protein. The patient died shortly following the test, thus no biological therapy was performed. Comparable data regarding treatment of melanoma patients with rare BRAF mutations is lacking, and the response to BRAF inhibitors requires further investigation.

View Figures

View References

1	Greaves WO, Verma S, Patel KP, Davies MA, Barkoh BA, Galbincea JM, Yao H, Lazar AJ, Aldape KD, Medeiros LJ and Luthra R: Frequency and spectrum of BRAF mutations in a retrospective, single-institution study of 1112 cases of melanoma. J Mol Diagn. 15:220–226. 2013. View Article : Google Scholar : PubMed/NCBI
2	Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, Teague J, Woffendin H, Garnett MJ, Bottomley W, et al: Mutations of the BRAF gene in human cancer. Nature. 417:949–954. 2002. View Article : Google Scholar : PubMed/NCBI
3	Wan PT, Garnett MJ, Roe SM, Lee S, Niculescu-Duvaz D, Good VM, Jones CM, Marshall CJ, Springer CJ, Barford D and Marais R; Cancer Genome Project, : Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF. Cell. 116:855–867. 2004. View Article : Google Scholar : PubMed/NCBI
4	Beck D, Niessner H, Smalley KS, Flaherty K, Paraiso KH, Busch C, Sinnberg T, Vasseur S, Iovanna JL, Drießen S, et al: Vemurafenib potently induces endoplasmic reticulum stress-mediated apoptosis in BRAFV600E melanoma cells. Sci Signal. 6:ra72013. View Article : Google Scholar : PubMed/NCBI
5	Long GV, Menzies AM, Nagrial AM, Haydu LE, Hamilton AL, Mann GJ, Hughes TM, Thompson JF, Scolyer RA and Kefford RF: Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma. J Clin Oncol. 29:1239–1246. 2011. View Article : Google Scholar : PubMed/NCBI
6	Heinzerling L, Kühnapfel S, Meckbach D, Baiter M, Kaempgen E, Keikavoussi P, Schuler G, Agaimy A, Bauer J, Hartmann A, et al: Rare BRAF mutations in melanoma patients: Implications for molecular testing in clinical practice. Br J Cancer. 108:2164–2171. 2013. View Article : Google Scholar : PubMed/NCBI
7	Dhillon AS and Kolch W: Oncogenic B-Raf mutations: Crystal clear at last. Cancer Cell. 5:303–304. 2004. View Article : Google Scholar : PubMed/NCBI
8	Jones DT, Kocialkowski S, Liu L, Pearson DM, Ichimura K and Collins VP: Oncogenic RAF1 rearrangement and a novel BRAF mutation as alternatives to KIAA1549: BRAF fusion in activating the MAPK pathway in pilocytic astrocytoma. Oncogene. 28:2119–2123. 2009. View Article : Google Scholar : PubMed/NCBI
9	Moretti S, Macchiarulo A, De Falco V, Avenia N, Barbi F, Carta C, Cavaliere A, Melillo RM, Passeri L, Santeusanio F, et al: Biochemical and molecular characterization of the novel BRAF(V599Ins) mutation detected in a classic papillary thyroid carcinoma. Oncogene. 25:4235–4240. 2006. View Article : Google Scholar : PubMed/NCBI
10	Schulten HJ, Salama S, Al-Mansouri Z, Alotibi R, Al-Ghamdi K, Al-Hamour OA, Sayadi H, Al-Aradati H, Al-Johari A, Huwait E, et al: BRAF mutations in thyroid tumors from an ethnically diverse group. Hered Cancer Clin Pract. 10:102012. View Article : Google Scholar : PubMed/NCBI
11	Gauchotte G, Philippe C, Lacomme S, Léotard B, Wissler MP, Allou L, Toussaint B, Klein M, Vignaud JM and Bressenot A: BRAF, p53 and SOX2 in anaplastic thyroid carcinoma: Evidence for multistep carcinogenesis. Pathology. 43:447–452. 2011. View Article : Google Scholar : PubMed/NCBI
12	Barollo S, Pezzani R, Cristiani A, Redaelli M, Zambonin L, Rubin B, Bertazza L, Zane M, Mucignat-Caretta C, Bulfone A, et al: Prevalence, tumorigenic role, and biochemical implications of rare BRAF alterations. Thyroid. 24:809–819. 2014. View Article : Google Scholar : PubMed/NCBI
13	Eisenhardt AE, Olbrich H, Röring M, Janzarik W, Anh TN, Cin H, Remke M, Witt H, Korshunov A, Pfister SM, et al: Functional characterization of a BRAF insertion mutant associated with pilocytic astrocytoma. Int J Cancer. 129:2297–2303. 2011. View Article : Google Scholar : PubMed/NCBI
14	Yu J, Deshmukh H, Gutmann RJ, Emnett RJ, Rodriguez FJ, Watson MA, Nagarajan R and Gutmann DH: Alterations of BRAF and HIPK2 loci predominate in sporadic pilocytic astrocytoma. Neurology. 73:1526–1531. 2009. View Article : Google Scholar : PubMed/NCBI